Insider Selling: ImmunityBio (NASDAQ:IBRX) Director Sells 25,000 Shares of Stock

ImmunityBio, Inc. (NASDAQ:IBRX) Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $7.51, for a total transaction of $187,750.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Christobel Selecky also recently made the following trade(s):

• On Friday, January 16th, Christobel Selecky sold 50,000 shares of ImmunityBio stock. The shares were sold at an average price of $5.00, for a total value of $250,000.00.

ImmunityBio Stock Performance

Shares of NASDAQ:IBRX traded up $0.44 on Wednesday, hitting $6.92. 95,661,091 shares of the company were exchanged, compared to its average volume of 33,482,678. The firm has a market capitalization of $6.82 billion, a price-to-earnings ratio of -16.88 and a beta of 0.03. ImmunityBio, Inc. has a one year low of $1.83 and a one year high of $7.98. The company’s 50 day moving average price is $2.54 and its two-hundred day moving average price is $2.52.

ImmunityBio (NASDAQ:IBRX) last announced its earnings results on Wednesday, November 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. The firm had revenue of $32.06 million for the quarter, compared to analyst estimates of $31.88 million. Research analysts predict that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

Institutional Trading of ImmunityBio

Several large investors have recently added to or reduced their stakes in the business. Slow Capital Inc. purchased a new position in ImmunityBio during the third quarter valued at approximately $25,000. Truist Financial Corp bought a new position in ImmunityBio during the third quarter valued at approximately $27,000. Swiss Life Asset Management Ltd bought a new stake in ImmunityBio in the third quarter worth $27,000. Diversify Advisory Services LLC purchased a new stake in shares of ImmunityBio during the 2nd quarter valued at about $27,000. Finally, Summit X LLC purchased a new position in shares of ImmunityBio in the 2nd quarter worth approximately $28,000. 8.58% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on IBRX. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Piper Sandler lifted their target price on ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a report on Tuesday. D. Boral Capital reiterated a “buy” rating and set a $24.00 price target on shares of ImmunityBio in a research note on Tuesday. Finally, Jefferies Financial Group raised their price target on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, ImmunityBio presently has an average rating of “Moderate Buy” and an average price target of $12.00.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA discussions gave ImmunityBio a clear path to resubmit an sBLA for ANKTIVA in papillary non‑muscle invasive bladder cancer, and the company plans to submit additional information within 30 days — a direct catalyst for upside. ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
• Positive Sentiment: Company press release confirmed a Type B End‑of‑Phase meeting with the FDA and outlined next steps for ANKTIVA’s sBLA, reinforcing the regulatory-path narrative that investors are rewarding. ImmunityBio Advances Regulatory Discussions with FDA
• Positive Sentiment: HC Wainwright raised its long‑term outlook (FY2030 EPS estimate to $0.68), signaling growing analyst optimism about ImmunityBio’s future earnings power (consensus had been negative).
• Positive Sentiment: At least one independent shop reaffirmed a “buy” and a high price target ($24), which may support further speculative buying interest. Benzinga
• Neutral Sentiment: The stock’s rally has extended over multiple sessions (reported as a 12‑day run in some outlets), driven in part by momentum trading and heavy volume rather than fresh clinical data. ImmunityBio (IBRX) rockets on 12th day, hits fresh high
• Neutral Sentiment: Market coverage notes short‑sellers are under pressure as the rapid share surge forces potential covering — a technical factor that can amplify volatility but isn’t a fundamental guarantee of sustained gains. Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses
• Neutral Sentiment: Multiple outlets covered the FDA meeting and ensuing price moves; much of the market reaction reflects expectations about the timing and sufficiency of the planned resubmission analyses. ImmunityBio stock soars after FDA meeting on bladder cancer treatment
• Negative Sentiment: Some analysts and commentary warn of momentum risks — advising traders to be cautious or to trim exposure amid a speculative rally and the possibility that regulatory requests could require more data or time than investors expect. Top 3 Health Care Stocks You May Want To Dump In January

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.